TOKYO -- Fujifilm Holdings' pending acquisition of Wako Pure Chemical Industries marks a big step forward for the company's regenerative medicine business, seen helping drive growth as traditional mainstay operations sag.
The Japanese imaging company's board on Thursday approved a plan to have core unit Fujifilm acquire the research reagents maker from Takeda Pharmaceutical by April 2017 via a 154.7 billion yen ($1.31 billion) tender offer starting in late February. Wako will also repurchase more than 30% of its own shares at the time of the acquisition at a cost of 97 billion yen.
